Polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of swine

Abstract

The invention provides a polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of a swine and a preparation method thereof. The polyvalent inactivity vaccine contains inactivated Bordetella bronchiseptica, Pasteurella multocida A, Pasteurella multocida D and PMT (Pasteurella Multocida Toxin) anatoxin. The invention further provides a novel method for culturing and extractingPMT. Compared with the traditional atrophic rhinitis of the swine, the polyvalent inactivity vaccine for the atrophic rhinitis of the swine, provided by the invention, can be used for more generally and effectively treating and preventing the atrophic rhinitis of the swine by comprehensive antigen protection. Finally, in the polyvalent vaccine provided by the invention, the vaccine with a plurality of antigens in a reasonable proportion can be used for solving the problem that the plurality of the antigens interfere each other, thereby improving an immune effect. Furthermore, the inventor provides a water adjuvant by which defects such as incomplete absorption, large side reaction and the like after the traditional alumina gel adjuvant, Freund adjuvant and water-in-oil adjuvant are injected into the water adjuvant can be overcome.

Description

technical field [0001] The invention relates to a multivalent inactivated vaccine for preventing and treating porcine atrophic rhinitis, in particular to a water-based adjuvant inactivated vaccine for porcine atrophic rhinitis containing multiple antigens. Background technique [0002] Porcine atrophic rhinitis (atrophic rhinitis, AR) is an important respiratory infectious disease in pigs. It can cause symptoms such as chronic rhinitis, sneezing, tearing, facial degeneration and turbinate atrophy in pigs. It can cause snout deformation and affect the bone development of the whole body, thereby causing growth retardation of pigs, making pigs susceptible to secondary complex pneumonia, and causing huge losses to the pig industry. The disease can infect pigs of any age, among which the infection rate of pigs within 4 weeks of age is the highest, and symptoms generally appear at 8-12 weeks of age. [0003] Porcine atrophic rhinitis can be divided into progressive atrophic rhini...

AI Technical Summary

Problems solved by technology

However, the steps for producing PMT toxoid are complicated. In the prior art, the toxin-producing strain Pm of Pasteurella multocida is cultivated for up to 26 hours with blood medium at 37°C, or the brain-heart extract meat After culturing the brain heart infusionbroth (BHI broth) for 72 hours, extract and concentrate PMT, and inactivate the harvested toxin with 1% formalin at 37°C for 4 days to obtain low toxicity but still antigenic toxoid

Therefore, in addition to the cumbersome preparation methods, the cost of preparing PMT inactivated into vaccine antigens is very high, which also limits the application of PMT in swine atrophic rhinitis.

[0006] At present, the porcine atrophic rhinitis vaccine used in my country is mainly Bordetella bronchiseptica (Bb) inactivated vaccine or Bordetella bronchiseptica (Bb) plus toxin-producing Pasteurella multocida type D (Pm- D) Inactivated vaccines, the adjuvants used are usually aluminum gel adjuvant, Freund's adjuvant, and water-in-oil adjuvant, which have few protective antigen components, cannot provide complete protection, and are not fully absorbed after injection. , side effects and other disadvantages

Images